Perrigo Company plc Outstanding Bonds
Note series still outstanding, nearest maturity first. Terms are from each offering's final pricing term sheet on SEC EDGAR; a reopening of the same CUSIP adds to its principal. Interest per payment = principal × coupon ÷ payments per year. Outstanding = principal issued minus each filed exchange, tender, redemption or conversion; it is (m) where the retired amount was not filed. Interest per payment uses the outstanding principal.
- 3.150% Senior Notes due 2030: Principal issued $750.00M; Outstanding $750.00M; Coupon 3.15%; Trade date 2020-06-16.
- 5.375% Senior Notes due 2032: Principal issued €350.00M; Outstanding €350.00M; Coupon 5.38%; Trade date 2024-09-11.
- 6.125% Senior Notes due 2032: Principal issued $715.00M; Outstanding $715.00M; Coupon 6.13%; Trade date 2024-09-11.
| Notes | Principal issued | Outstanding | Coupon | Trade date | Issue / settlement date | Maturity date | Interest payment dates | Interest per payment | Annual coupon interest | Optional redemption | Retired | Priced |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.150% Senior Notes due 2030 CUSIP 71429MAC9 · US71429MAC91 Listed on NYSE: 10-K 2022-03-01 to 10-Q 2022-05-11 cover | $750.00M | $750.00M | 3.15% | 2020-06-16 | 2030-06-15 | Semi-annually: June 15, December 15 | $11.81M | $23.63M | At par from 2030-03-15 | 2020-06-16 | ||
| 5.375% Senior Notes due 2032 CUSIP (m) · XS2903463987 Listed on NYSE: 10-Q 2024-11-06 to 10-Q 2026-08-05 cover | €350.00M | €350.00M | 5.38% | 2024-09-11 | 2032-09-30 | Annually: March 30 | €18.81M | €18.81M | On and after September 30, 2027, the Issuer may redeem the Euro Notes in whole at any time, or in part from time to time | 2024-09-12 | ||
| 6.125% Senior Notes due 2032 CUSIP 71429MAD7 · US71429MAD74 Listed on NYSE: 10-Q 2024-11-06 to 10-Q 2026-08-05 cover | $715.00M | $715.00M | 6.13% | 2024-09-11 | 2032-09-30 | Semi-annually: March 30, September 30 | $21.90M | $43.79M | On and after September 30, 2027, the Issuer may redeem the USD Notes in whole at any time, or in part from time to time, | 2024-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |